NCI Helps Children’s Hospital of Philadelphia to Identify and Treat New Target in Pediatric Cancer

There may be a new, more effective method for treating high-risk neuroblastoma, according to scientists at the Children’s Hospital of Philadelphia and collaborators in the Cancer and Inflammation Program at NCI at Frederick. Together, the groups published a study describing a previously unrecognized protein on neuroblastoma cells, called GPC2, as well as the creation of a novel antibody-drug conjugate, a combination of a human antibody and a naturally occurring anticancer drug, that locates and binds to GPC2 in a highly efficient way.


NIH–Lacks Family Partnership Gives Henrietta Lacks’ Descendants a Seat at the Table

The NIH Bethesda campus recently welcomed several special guests for a presentation titled Given a Voice: Update on the NIH–Lacks Family Partnership. Henrietta Lacks’ grandchildren Jeri Lacks-Whye (who is also the Lacks family spokesperson) and David Lacks, Jr. came to speak with NIH Director Francis S. Collins, Ph.D., M.D. about the importance of protecting patients and their families.


NCI Scientists Create New Assay, Identify Novel Therapeutic Compounds, and Take Places on Front Lines of Cancer Research

A team of scientists and specialists from NCI at Frederick, NCI at Bethesda, the Frederick National Laboratory for Cancer Research, and Data Management Services, Inc., has developed the first method for identifying natural products that could increase the effectiveness of camptothecin-based cancer treatments.



Subscribe to Science